Dabigatran is a novel anticoagulation which has been approved as an alternative to warfarin therapy for non-valvular atrial fibrillation. Use of Dabigatran for approved indications as well as off label use has dramatically increased after Federal Drug Administration (FDA) approval. Our patient had left atrial thrombosis even after being on Dabigatran for more than one month which raises question about safety and efficacy of use of dabigatran around cardioversion and ablation..
|Number of pages
|Journal of Atrial Fibrillation
|Published - Aug 1 2013
- Atrial fibrillation
- Left atrial thrombosis
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine